Latest Noven Pharmaceuticals Inc. Stories

MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 4 that the overall risk/benefit profile of low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) is not acceptable to support approval. LDMP is an investigational nonhormonal treatment specifically developed for moderate to severe vasomotor symptoms (VMS) associated...

MIAMI and NEW YORK, Jan. 29, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., the manufacturer of Vivelle-Dot(® )(estradiol transdermal system), today announced the availability of Minivelle(TM) (estradiol transdermal system) by prescription in U.S. pharmacies. On October 29, 2012, the U.S. Food and Drug Administration (FDA) approved Minivelle(TM) for the treatment of moderate to severe vasomotor symptoms due to menopause, commonly known as hot flashes and night sweats....

MIAMI, FL and NEW YORK, NY, Nov. 12, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP; 7.5 mg) for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the...

MIAMI, FL, NEW YORK, NY and ORLANDO, FL, Oct. 3, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Menopausal VMS, which comprise hot...

DUBLIN, October 29, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2010. Financial Highlights Q3 2010(2) Product sales(1) $794 million +32% Total revenues $874 million +31% Non GAAP operating income $298 million +123%...

TOSU, Saga, Japan and MIAMI, Aug. 27 /PRNewswire-FirstCall/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530) and Hisamitsu U.S., Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, Inc. pursuant to a short form merger of Northstar Merger Sub, Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and into Noven. Pursuant to the Agreement and Plan of Merger among the companies, at the effective time of the merger all remaining outstanding shares of...

TOSU, SAGA, Japan, Aug. 27 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530) today announced the expiration of the subsequent offering period and completion of the tender offer for all outstanding shares of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) common stock at a price per share of $16.50. The subsequent offering period expired at 12:00 midnight, New York City time, on Wednesday, August 26, 2009 and was not extended. As of such time, an aggregate of 22,320,889 shares of...

TOSU, SAGA, Japan, Aug. 20 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530), Hisamitsu U.S., Inc. and Northstar Merger Sub, Inc. today announced the completion of the initial tender offer period for all outstanding shares of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) common stock and the commencement of a subsequent offering period that will expire at 12:00 midnight on Wednesday, August 26, 2009, unless extended. As previously announced, on July 23, 2009, Hisamitsu...

TOSU, SAGA, Japan, Aug. 13 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530), Hisamitsu U.S., Inc. and Northstar Merger Sub, Inc., today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), at 11:59 p.m., New York City time, on August 12, 2009, with respect to the previously announced proposed acquisition of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN). Hisamitsu, through its wholly owned...

TOSU, SAGA, Japan, July 23 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530), Hisamitsu U.S., Inc. and Northstar Merger Sub, Inc., today commenced the cash tender offer to purchase all outstanding shares of common stock of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) contemplated by the Agreement and Plan of Merger executed and publicly announced by Hisamitsu and Noven on July 14, 2009. Upon the successful closing of the tender offer, shareholders of Noven will receive $16.50 in...